Neurol. praxi. 2009;10(6):340-346

Treatment of Parkinson’s disease

prof.MUDr.Ivan Rektor, CSc.
Centrum pro abnormní pohyby a parkinsonizmus, I. neurologická klinika LF MU a FN u sv. Anny, Brno

Start of the therapy: L-dopa; DA-agonists; selegiline; amantadine; rasagiline; in patients older than 70 years L-dopa. When therapy

insufficient: add on/increase the standard or controlled-released L-dopa, COMT inhibitor; DA-agonists orally or in patch; rasagiline. Severe

motor complication: partial „drug holiday” with amantadine i. v.; apomorphine/lisuride s. c.; intraduodenal L dopa; surgery (DBS).

Psychiatric complications: graduall discontinuation of DA agonists, amantadine, MAO inhibitors, anticholinergics; to continue with the

minimal effective dose of L-dopa; atypical antipsychotics. Dementia: acetylcholinesterase inhibitors.

Keywords: Parkinson’s disease, treatment, drugs, surgery, dopaminergic

Published: January 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rektor I. Treatment of Parkinson’s disease. Neurol. praxi. 2009;10(6):340-346.
Download citation

References

  1. Baláž M. Chirurgická terapie extrapyramidových onemocnění. Neurol. pro praxi 2009; 10(6): 348-352.
  2. Bareš M. Senzitivní příznaky Parkinsonovy nemoci. Česk Slov Neurol N. 2001; 64/97(3): 139-143.
  3. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20: 523-539. Go to original source... Go to PubMed...
  4. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel W, Poewe W, Rascol O, Sampaio C. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol. 2006a; 13(11): 1170-1185. Go to original source... Go to PubMed...
  5. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen JP, Lees A, Ortel W, Poewe W, Rascol O, Sampaio C. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006b; 13: 1186-1202. Go to original source... Go to PubMed...
  6. Kanovsky P, Kubova D, Bares M, Hortová H, Streitová H, Rektor I, Znojil V. L-DOPA Induced Dyskinesias and the Continuous Subcutaneous Infusions of Apomorphine - Results of a Two Years, Prospective Follow-up. Mov Disord 2002; 17: 188-191. Go to original source... Go to PubMed...
  7. Management of PD. An evidence-based review. Task force, The Movement Disorder Society. Mov Disord 2002; 17(Suppl. 4): 1-166. Go to original source... Go to PubMed...
  8. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Long AE. Initiation of treatment for PD: an evidence-based review. Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002; 58: 11-17. Go to original source... Go to PubMed...
  9. NICE clinical guideline 35. Parkinson's disease: diagnosis and management in primary and secondary care. National Institute for Health and Clinical Excellence: June 2006.
  10. Rektor I, Rektorová I a spolupracovníci. Centrální poruchy hybnosti v praxi: Movement disorders. Triton, Praha 2003: 194.
  11. Rektorová I. Současné možnosti diagnostiky a terapie Parkinsonovy nemoci. Neurol. pro praxi 2009; 10(Suppl. A): 38.
  12. Rektorová I. Akutní stavy s extrapyramidovou symptomatikou (movement disorder emergency). Neurol. pro praxi 2009; 10(6): 360-362.
  13. Rektorová I, Baláž M. Postup u psychotických komplikací Parkinsonovy nemoci. In: Rektor I, et al. (ed.) Parkinsonova nemoc: doporučené postupy diagnostiky a léčby II. Pozdní stadium. Praha, Galen 2004: p 23-25.
  14. Roth J. Depresivní porucha v neurologii: úspěšnost diagnostiky a terapie. In: Anders A, Uhrová T, Roth J. Depresivní porucha v neurologické praxi. Galén Praha 2005: pp.111-120.
  15. Ruzicka E, Streitová H, Jech R, Kaňovský P, Roth J, Rektorová I, Mečíř P, Hortová H, Bareš M, Hejduková B, Rektor I. Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease. J Neual Transm 2000; 107: 1297-1306. Go to original source... Go to PubMed...
  16. Shapira AHV and Olanow CW. Drug Selection and Timing of Initiation of Treatment in Early Parkinson's Disease. Ann Neurol 2008; 64(suppl): S47-S55. Go to original source... Go to PubMed...
  17. Valkovič P. Posturálna instabilita u pacientov s Parkinsonovou chorobou a jej liečba. Neurol. pro praxi 2009; 10(6): 363-368.




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.